PDF(Pubmed)
Abstract：
Few large studies have investigated quality of life (QOL) for adults diagnosed with lower grade glioma (LGG).
QOL was assessed for 320 adults with LGG (World Health Organization grade 2/3) enrolled in the International Low Grade Glioma Registry by using the Medical Outcomes Study 36-Item Short Form health survey. Data on symptoms were also collected. QOL outcomes were examined by treatment group and also compared to those from a population-based case-control study of meningioma (the Meningioma Consortium), in which 1722 meningioma cases diagnosed among residents of Connecticut, Massachusetts, California, Texas, and North Carolina from May 1, 2006 through March 14, 2013 were enrolled and frequency matched to 1622 controls by age, sex, and geography.
The LGG sample average age is 45 years at the time of interview and 53.1% male. Almost 55% of patients had received radiation and chemotherapy (primarily temozolomide); 32.4% had received neither treatment. Two-thirds of participants with LGG report difficulty with speaking, memory, or thinking, and over one of three reports personality change or difficulty driving. After controlling for age and other comorbidities, individuals with LGG report levels of physical, emotional, and mental health functioning below those reported in a meningioma as well as a general healthy population.
Despite being relatively young, persons with LGG report significantly reduced QOL compared to persons with nonmalignant brain tumors and to a control population, which highlights the need to better acknowledge and manage these symptoms for this group of patients diagnosed in the prime of life.
QOL was assessed for 320 adults with LGG (World Health Organization grade 2/3) enrolled in the International Low Grade Glioma Registry by using the Medical Outcomes Study 36-Item Short Form health survey. Data on symptoms were also collected. QOL outcomes were examined by treatment group and also compared to those from a population-based case-control study of meningioma (the Meningioma Consortium), in which 1722 meningioma cases diagnosed among residents of Connecticut, Massachusetts, California, Texas, and North Carolina from May 1, 2006 through March 14, 2013 were enrolled and frequency matched to 1622 controls by age, sex, and geography.
The LGG sample average age is 45 years at the time of interview and 53.1% male. Almost 55% of patients had received radiation and chemotherapy (primarily temozolomide); 32.4% had received neither treatment. Two-thirds of participants with LGG report difficulty with speaking, memory, or thinking, and over one of three reports personality change or difficulty driving. After controlling for age and other comorbidities, individuals with LGG report levels of physical, emotional, and mental health functioning below those reported in a meningioma as well as a general healthy population.
Despite being relatively young, persons with LGG report significantly reduced QOL compared to persons with nonmalignant brain tumors and to a control population, which highlights the need to better acknowledge and manage these symptoms for this group of patients diagnosed in the prime of life.
摘要：
背景：很少有大型研究调查诊断为低级别神经胶质瘤（LGG）的成年人的生活质量（QOL）。
方法：采用医学结果研究36项简表健康调查，对在国际低度胶质瘤登记处登记的320名LGG（世界卫生组织2/3级）成人进行了生活质量评估。还收集了症状数据。按治疗组检查QOL结果，并与基于人群的脑膜瘤病例对照研究（脑膜瘤联盟）进行比较。在康涅狄格州的居民中诊断出1722例脑膜瘤病例，马萨诸塞州,加州,德州,和北卡罗来纳州从2006年5月1日至2013年3月14日登记，频率按年龄与1622名对照相匹配，性别,和地理。
结果：LGG样本在访谈时的平均年龄为45岁，男性占53.1％。几乎55％的患者接受过放疗和化疗（主要是替莫唑胺）；32.4％的患者没有接受过任何治疗。三分之二的LGG参与者报告说话困难，记忆,或者思考，以及超过三份报告中的一份人格改变或驾驶困难。在控制了年龄和其他合并症之后，LGG的个人报告身体水平，情感,和心理健康功能低于脑膜瘤和一般健康人群的报告。
结论：尽管相对年轻，与非恶性脑肿瘤患者和对照人群相比，LGG患者的生活质量显着降低，这突出了需要更好地承认和管理这些症状的这组患者在生命的黄金时期诊断。
方法：采用医学结果研究36项简表健康调查，对在国际低度胶质瘤登记处登记的320名LGG（世界卫生组织2/3级）成人进行了生活质量评估。还收集了症状数据。按治疗组检查QOL结果，并与基于人群的脑膜瘤病例对照研究（脑膜瘤联盟）进行比较。在康涅狄格州的居民中诊断出1722例脑膜瘤病例，马萨诸塞州,加州,德州,和北卡罗来纳州从2006年5月1日至2013年3月14日登记，频率按年龄与1622名对照相匹配，性别,和地理。
结果：LGG样本在访谈时的平均年龄为45岁，男性占53.1％。几乎55％的患者接受过放疗和化疗（主要是替莫唑胺）；32.4％的患者没有接受过任何治疗。三分之二的LGG参与者报告说话困难，记忆,或者思考，以及超过三份报告中的一份人格改变或驾驶困难。在控制了年龄和其他合并症之后，LGG的个人报告身体水平，情感,和心理健康功能低于脑膜瘤和一般健康人群的报告。
结论：尽管相对年轻，与非恶性脑肿瘤患者和对照人群相比，LGG患者的生活质量显着降低，这突出了需要更好地承认和管理这些症状的这组患者在生命的黄金时期诊断。
